Stockwinners Market Radar for August 02, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:57 EDT TrueCar still sees FY22 adjusted EBITDA to be negative - "There remains considerable uncertainty across the automotive industry due to global supply chain issues and the continuing automobile microchip shortages, particularly for new vehicles," the company said. "Vehicle inventories have remained at low levels as compared to historical levels while pricing remains well above average. We expect new vehicle supply constraints and low dealer inventories to persist throughout 2022. Aside from this, we see the potential for consumer demand to weaken due to elevated vehicle prices and the potential for higher financing costs as the Federal Reserve raises interest rates. The combination of these and other factors likely means that our close rates and reported units will remain under pressure during the balance of 2022 and may lag should future improvements in automobile market dynamics occur. Due to these factors, we are not providing quarterly guidance. However, we plan to continue to invest in TrueCar+ and other strategic initiatives that, we believe, will position us for future growth and increased monetization. We continue to expect Adjusted EBITDA to be negative during 2022 with the second half of the year showing a greater impact from contemplated investments in marketing, technology, and other support for TrueCar+ as we expand beyond Florida."

18:38 EDT Airbnb CEO: We are very optimistic, feel very confident about Q3 - In an interview on CNBC's Mad Money, Brian Chesky said Airbnb is seeing "metronomic improvements" in free cash flow. The company's free cash flow over the past year was nearly $3B, he noted. Longer stays are still going strong, and Airbnb plans to be aggressive with new growth opportunities, he added. "We used to be known as an app for younger people, but it has grown to all demos," he said.

18:16 EDT Nikola announces stockholders approved Proposal 2 - Nikola announced that stockholders have voted to approve Proposal 2 at the Company's 2022 Annual Meeting of Stockholders. This proposal will allow Nikola to increase the number of authorized shares from 600M to 800M. At the 2022 Annual Meeting of Stockholders on August 2, a majority of all outstanding common stock voted to approve Proposal 2, the Amendment to the Second Amended and Restated Certificate of Incorporation to Increase the Authorized Number of Shares of Common Stock. More than 66% of votes cast, or more than 211M shares, were in favor of Proposal 2. After initially adjourning its annual meeting on June 1 Nikola had received the necessary number of votes from stockholders to approve Proposals 1, 3, and 4. These proposals were related to election of directors, a non-binding advisory vote on compensation of named executive officers, and ratification of Nikola's independent registered public accounting firm. Final results of the vote will be certified and reported on a Form 8-K that Nikola will file with the SEC.

17:44 EDT Starbucks says guidance still suspended for balance of FY22 - Sees Q4 margin lower than Q3. Says increasing COVID-19 cases a threat to growth. Sees U.S. investments doubling from Q3 to Q4. Sees margin headwinds worsening in Q4.

17:35 EDT VP of Comfort Systems Julie Shaeff sells $1.3M in shares - VP of Comfort Systems Julie Shaeff disclosed in a filing that she had sold 12,849 shares of company stock at $104.09 per share on August 1, for a total transaction amount of $1,337,419.

17:30 EDT Pear Therapeutics to be added to Russell US Index Series - Pear Therapeutics announced that it will be added to the Russell US Index Series in conjunction with the September 2022 quarterly review, effective after the US market open on Monday, September 19, 2022. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

17:23 EDT Lumen awarded $1.5B Defense Information Systems Agency contract - Lumen was awarded a firm-fixed-price, indefinite-delivery/indefinite-quantity contract with a maximum ceiling amount of $1.5B for Indo-Pacific Transport Services, to provide end-to-end transmission services and capabilities essential to the Defense Information System Network, or DISN, Indo-Pacific, the Department of Defense's consolidated enterprise level telecommunications infrastructure for the U.S. Indo-Pacific Command area of responsibility, to include Alaska. The contract consists of a 10-year performance period; individual orders will be funded by the Defense Working Capital Fund. Proposals were solicited via SAM.gov and three offers were received. The period of performance is August 31 to August 30, 2032. The Defense Information Technology Contracting Organization is the contracting activity.

17:21 EDT Starbucks says U.S. customers not trading down to cheaper items - Says U.S. Starbucks (SBUX) customers not trading down to cheaper items amid inflation. Says planning to open stores in Rome and Florence. Says partnership with Nestle (NSRGY) "highly accretive" to business. Says expects closer Starbucks-Nestle partnershhip in the future.

17:11 EDT Starbucks says Q3 results demonstrate 'significant' progress - Says not seeing measurable reduction in customer spending amid current macroeconomic trends. Says Q3 results demonstrate "significant" progress made in just the last few months. Says Starbucks experience is "more relevant" than ever in "today's unsettled world." Says executing against reinvention plan with deep sense of urgency. Says continues to extend coffee leadership. Says cold beverages now account for larger portion of total U.S. sales. Comments taken from Q3 earnings conference call.

17:05 EDT Manitowoc announces Jennifer Peterson as interim general counsel - Manitowoc announced that Jennifer Peterson, currently the company's interim general counsel and assistant secretary, has been appointed executive VP, general counsel and secretary effective immediately. Peterson joins the executive leadership team with more than 20 years of legal experience from both in-house and private practice. Prior to her appointment, Peterson served as Manitowoc's interim general counsel and assistant secretary since May.

16:59 EDT Codexis enters license, enzyme supply agreement with Molecular Assemblies - Codexis announced the execution of a commercial license and enzyme supply agreement, enabling Molecular Assemblies to utilize an evolved terminal deoxynucleotidyl transferase, or TdT, enzyme in Molecular Assemblies' Fully Enzymatic Synthesis technology. The companies collaborated to develop this supercharged TdT enzyme to advance fully enzymatic DNA synthesis for the production of long, pure, accurate oligonucleotides to accelerate innovation in many fields. Molecular Assemblies plans to first make its FES technology available via an early access key customer program, opening later this year. The financial terms of the agreement include milestone payments from Molecular Assemblies to Codexis and royalties on sales of oligonucleotides synthesized using FES technology. Under the terms of the agreement, Molecular Assemblies has exclusively licensed the Codexis evolved TdT enzyme for commercial use in DNA synthesis.

16:53 EDT MDxHealth acquires Oncotype DX from Exact Sciences for $100M in cash, stock - MDxHealth (MDXH) announced it has entered into an asset purchase agreement with Genomic Health, a subsidiary of Exact Sciences (EXAS), to acquire the Oncotype DX GPS test from Exact Sciences along with most of its team of urology sales and marketing professionals. Under the terms of the asset purchase agreement, Mdxhealth acquired the Oncotype DX GPS prostate cancer business of Exact Sciences for an aggregate purchase price of up to $100M, of which an amount of $25M was paid in cash and an amount of $5M will be settled through the delivery of 691,171 American Depositary Shares of the company, at a price per ADS of $7.23. Following the closing, which took place, an additional aggregate earn-out amount of up to $70M is to be paid by Mdxhealth to Exact Sciences upon achievement of certain revenue milestones related to fiscal years 2023 through 2025, with the maximum earn-out payable in relation to 2023 and 2024 not to exceed $30M and $40M, respectively. At the option of Mdxhealth, the earn-out amounts can be settled in cash or through the issuance of additional ADSs of the company to Exact Sciences, provided that the aggregate number of shares representing the ADSs held by Exact Sciences shall not exceed more than 5% of the outstanding shares of Mdxhealth.

16:52 EDT Revance expects cash to fund operations into 2024 - Revance expects 2022 GAAP operating expenses to be $375 million to $400 million and non-GAAP operating expenses, which exclude costs of revenue, depreciation and amortization and stock-based compensation, to be $260 million to $280 million. Revance expects 2022 non-GAAP research and development expense to be $100 million to $110 million. With the current cash, cash equivalents and short-term investments, management projects that the company is funded into 2024, with additional $100 million in notes available under the company's note purchase agreement, subject to the FDA approval of DaxibotulinumtoxinA for Injection for glabellar lines.

16:48 EDT CommScope selected by SS&E to provide mobile connectivity at AT&T Center - CommScope announced it has been selected by Spurs Sports & Entertainment, SS&E, as the provider for its next generation mobile connectivity transformation at AT&T Center. With CommScope's ERA All-Digital DAS, the AT&T Center will increase its mobile broadband wireless capacity to provide an augmented fan experience utilizing ultra-wideband 5G. "This enables fans to enjoy frictionless event-day conveniences such as immersive content, paperless entry, cashless payments, and in-seat ordering with their smartphones," the company said. In addition to being selected as the in-building cellular platform for fan facing mobile broadband, SS&E selected CommScope CBRS to provide the AT&T Center with its first private wireless network, dedicated to operations and enhanced security around the arena.

16:43 EDT E.W. Scripps approves new contract for CEO Adam Symson - The board of directors of The E.W. Scripps Company has approved a new contract for Scripps President and CEO Adam Symson that runs through Dec. 31, 2027. The new agreement replaces a three-year contract that began Jan. 1, 2020.

16:37 EDT Herbalife Nutrition invests $400M in digital transformation initiative - Herbalife Nutrition announced Herbalife One, a new digital transformation initiative centered around launching a single platform that creates a simplified and integrated experience for distributors and their customers around the world. As a key driver for future growth objectives, the Herbalife One platform will be built around new technologies and streamlined processes, resulting in greater efficiencies and productivity. "We are excited to announce the board's approval to proceed with our new digital transformation platform, the largest single investment in the company's history," said John Agwunobi, Chairman and CEO of Herbalife Nutrition. "The design of this new seamless platform experience is a result of extensive collaboration with our distributors to identify a technology that will enable our future growth, by delivering a best-in-class digital experience for all distributors and their customers." The investment of over $400 million includes an incremental expenditure of up to $250 million over the next three years.

16:36 EDT MiMedx maintains outlook for FY22 - The company is maintaining its outlook for 2022, as disclosed in its earnings release for the year ended December 31, 2021, including that it expects net sales of its continuing portfolio of Advanced Wound Care products, which were $240.0 million in 2021, to grow 11% to 14% in 2022. These expectations reflect the company's plans to launch AMNIOEFFECT and its Placental Collagen Matrix product, AXIOFILL, in the U.S. in September, as well as the launch of EPIFIX in Japan later this year.

16:35 EDT Exact Sciences enters collaboration with West German Study Group - Exact Sciences announced that it has entered a collaboration agreement with the West German Study Group, an international research institution that focuses on practice-changing clinical studies in breast cancer. Together, Exact Sciences and WSG plan to conduct a prospective, multicenter validation study in hormone receptor-positive, HER2-negative early breast cancer patients. The study is intended to demonstrate the ability of Exact Sciences' tumor-informed ctDNA liquid biopsy test to detect minimal residual disease and to collect important long-term follow-up and outcome data. The combined analysis, called ADAPT Triad, is expected to include data from approximately 3,000 German patients enrolled in two ongoing WSG ADAPT trials and one WSG registry study. All patients included in the analysis are stratified using the Oncotype DX Breast Recurrence Score test. The study is part of Exact Sciences' global initiative to generate clinical validation data for its tumor-informed ctDNA MRD liquid biopsy test, currently in development.

16:33 EDT VIA Optronics names Roland Chochoiek CMO - VIA optronics AG announced the appointment of Roland Chochoiek as Chief Marketing Officer, effective August 1, 2022. In this senior leadership role, Roland will report to Jurgen Eichner, CEO and founder of VIA optronics. As CMO, Roland will lead VIA's go-to-market strategy in support of the Company's long-term growth plans. Jurgen Eichner, CEO and founder of VIA optronics AG commented, "We are very excited to welcome Roland as our new CMO. With his extensive experience in custom-oriented, electronic solutions and strong international background, we believe Roland will be a driving force on our path toward sustainable, long-term growth and profitability." Roland Chochoiek added, "I am honored to be joining VIA optronics at such a pivotal time for the Company. VIA has a sophisticated and exciting product suite that's highly relevant to the growing and diverse display market, particularly for the automotive and industrial end markets. I look forward to leveraging my sales and marketing experience as we continue to launch innovative display systems and touch sensor solutions."

16:31 EDT ModivCare CEO Greenleaf to leave company, Sampson named interim CEO - Modivcare announced that the Company's Chief Financial Officer, L. Heath Sampson, has been appointed Interim Chief Executive Officer, effective immediately. In connection with this announcement, Daniel E. Greenleaf is no longer serving as Chief Executive Officer and a member of the Company's Board of Directors. The Modivcare Board has commenced a search process to identify Modivcare's next CEO. Chris Shackelton, Chairman of the Modivcare Board, said, "In an effort to better serve our stakeholders and position the Company as the leading supportive care provider in the nation, Modivcare has undergone a significant transformation over the last few years. The Board has determined that now is the right time to transition to our next phase of leadership. We are fortunate to have a leader of Heath's caliber and experience step into the CEO role on an interim basis. Heath knows the company well, and we are confident he is the right person to lead Modivcare and help continue to deliver profitable growth."

16:29 EDT PayPal jumps 13% to $101.25 after buyback plan, Elliott agreement

16:26 EDT Pioneer Natural Q3 oil production forcasted between 345 to 360 MBOPD - Third quarter 2022 oil production is forecasted to average between 345 to 360 MBOPD and total production is expected to average between 635 to 660 thousand barrels of oil equivalent per day, MBOEPD. Production costs are expected to average $12.00 per BOE to $13.50 per BOE. DD&A expense is expected to average $10.50 per BOE to $12.00 per BOE. Total exploration and abandonment expense is forecasted to be $10 million to $20 million. G&A expense is expected to be $75 million to $85 million. Interest expense is expected to be $30 million to $35 million. Other expense is forecasted to be $20 million to $40 million. Accretion of discount on asset retirement obligations is expected to be $3 million to $6 million. The cash flow impact related to purchases and sales of oil and gas, including firm transportation, is expected to be a loss of $60 million to a loss of $100 million, based on forward oil price estimates for the quarter. The Company's effective income tax rate is expected to be between 22% to 27%, with cash taxes expected to be $300 million to $350 million, representing estimated federal and state tax payments that will be paid based on forecasted 2022 taxable income.

16:26 EDT A10 Networks backs FY22 EBITDA growth view 26%-28% of revenue - "We have been able to successfully navigate supply chain challenges and input cost pressures, as evidenced by our stable gross margins, and we expect these challenges will persist for some time," continued Trivedi. "We reiterate our full year targets around top line growth of 10 - 12% and expanding EBITDA in the range of 26 - 28% of revenue. Our targeted, strategic investments in technology are enabling us to capture market share, while our diversity of revenue and cybersecurity solutions serve as catalysts for durable growth, even amidst macroeconomic conditions."

16:24 EDT Sonder Holdings names Deeksha Hebbar COO - Sonder Holdings announced the appointment of Deeksha Hebbar as Chief Operating Officer, and Chris Berry as Senior Vice President and Chief Accounting Officer. Sonder recently consolidated its operations teams, streamlining frontline market-level operations and its centralized support service operations. In the role of Chief Operating Officer, Hebbar will lead this combined team, overseeing all Sonder operations including turning over units, opening and maintaining properties, and delivering service to guests. Hebbar was previously SVP of Operations at Sonder, and prior to Sonder held roles at technology and consulting businesses including Google Inc. and McKinsey & Company.

16:21 EDT PayPal appoints Blake Jorgensen as CFO - "Blake has extensive experience driving operational excellence and shareholder value, having served as CFO at industry-leading companies including Electronic Arts Inc., Levi Strauss & Co., and Yahoo! Inc.," the company said.

16:20 EDT Unum Group raises FY22 after-tax adjusted operating income outlook - "The company expects positive operating trends in our core business during 2022, with solid premium growth and improving claim experience as impacts from COVID-19 lessen. The company also anticipates an increase in after-tax adjusted operating income per share of 40 percent to 45 percent relative to full-year 2021, compared to its previous outlook of an increase of 15 percent to 20 percent. The increased expectation reflects the company's strong first half performance and an improved outlook for the balance of 2022."

16:20 EDT Ingevity invests $60M in lithium-ion anode materials producer Nexeon - Ingevity announced that it has invested $60 million to acquire an equity stake in Nexeon Limited in a strategic move to establish the company's presence in the electric vehicle market and expand opportunities to grow its activated carbon business. Ingevity's funding will enable Nexeon to further develop its proprietary next-generation silicon anode material, NSP-2, and facilitate the construction of manufacturing facilities for the commercialization of Nexeon's innovative products. Nexeon's customers have found that NSP-2 offers a step-change improvement in lithium-ion battery performance while also reducing the weight of the battery. "Today's announcement marks an important milestone in our company's history, and underscores Ingevity's long-term vision for growth and commitment to exploring value-added applications for our activated carbon in expanding markets like EVs," said Ingevity president & CEO, John Fortson. "Nexeon has established itself as an innovation leader within what will likely be a rapidly growing space for years to come, and we are excited to partner with them to advance their game-changing patented technologies."

16:17 EDT Alpha Capital Acquisition holders approve Semantix deal - Alpha Capital Acquisition Company announced that Alpha Capital's shareholders voted to approve its proposed business combination with Semantix, Latin America's first fully integrated data platform and Brazil's first deep tech company to be listed at Nasdaq. The vast majority of the votes cast at the meeting voted to approve the transaction. The business combination is scheduled to close on August 3, 2022 and the post-closing company will be renamed "Semantix, Inc." The common stock and warrants of the combined company are set to begin trading on Nasdaq on August 4, 2022 under the new ticker symbols, "STIX" and "STIXW", respectively.

16:17 EDT Robinhood cuts 23% of workforce amid reduced customer activity - Robinhood CEO Vlad Tenev said in a blog post, "As part of a broader company reorganization into a General Manager structure, I just announced that we are reducing our headcount by approximately 23%. While employees from all functions will be impacted, the changes are particularly concentrated in our operations, marketing, and program management functions...Let me explain how we arrived at this decision. Earlier this year, I announced that we would be letting go of 9% of our workforce and focusing on greater cost discipline throughout the organization. This did not go far enough. Since that time, we have seen additional deterioration of the macro environment, with inflation at 40-year highs accompanied by a broad crypto market crash. This has further reduced customer trading activity and assets under custody. Last year, we staffed many of our operations functions under the assumption that the heightened retail engagement we had been seeing with the stock and crypto markets in the COVID era would persist into 2022. In this new environment, we are operating with more staffing than appropriate. As CEO, I approved and took responsibility for our ambitious staffing trajectory - this is on me." Reference Link

16:15 EDT Postal Realty Trust increases quarterly dividend to 23.25c per share - On July 27, 2022, the company declared a quarterly dividend of 23.25c per share of Class A common stock. The dividend equates to 93c per share on an annualized basis. This represents the twelfth consecutive dividend increase since the company's IPO in 2019. The dividend will be paid on August 26, 2022 to stockholders of record as of the close of business on August 8, 2022.

16:14 EDT Knowles announces restructuring program within Audio segment - Knowles announced a restructuring program within its Audio segment designed to right size manufacturing capacity and operating expenses in its MEMS Microphones product line. Restructuring charges are expected to be $35-$45 million, including $23-$28 million in cash payments, with estimated annualized savings of $25-$30 million. This restructuring program is expected to be completed in the fourth quarter of 2022.

16:06 EDT Starbucks says FY22 guidance remains suspended for balance of the year

16:05 EDT Mandiant to not provide guidance due to pending transaction with Google - Given the announcement made on March 8, 2022, regarding the company's entry into a definitive agreement to be acquired by Google (GOOG;GOOGL), Mandiant (MNDT) will not be providing financial guidance for the third quarter of 2022 or updated financial guidance for the full-year 2022. The company's previously issued full-year 2022 financial guidance should no longer be relied upon. Due to the pending transaction with Google, Mandiant will not host a conference call in conjunction with this release. For further detail and discussion of the company's financial performance, please refer to Mandiant's upcoming quarterly report on Form 10-Q for the second quarter ended June 30, 2022.

16:04 EDT Magnolia Oil & Gas sees 2022 production up 12%-14% over 2021 - The company said, "Magnolia has shown consistent and steady production growth due to strong well performance and faster cycle times. Additional non-operated activity has increased in the Eagle Ford which has contributed to both higher production and capital. As a result, we now expect our full-year 2022 production to grow by 12 to 14 percent compared to 2021. Third quarter production is expected to be 74 to 76 Mboe/d and D&C capital is expected to be in the range of $105 to $115 million. Oil price differentials are anticipated to be approximately a $2 to $3 per barrel discount to Magellan East Houston and Magnolia remains completely unhedged for all its oil and natural gas production. The fully diluted total share count for the third quarter of 2022 is expected to be approximately 219 million shares which is 7 percent lower than third quarter 2021 levels."

16:03 EDT MicroStrategy says Michael Saylor to assume new role of exec chairman - MicroStrategy announced that, as of August 8, 2022, Michael Saylor will assume the new role of Executive Chairman and Phong Le, the Company's President, will also serve as the Company's new Chief Executive Officer and as a member of the Board of Directors. Mr. Saylor will remain the Chairman of the Board of Directors and an executive officer of the Company. Michael Saylor has served as Chief Executive Officer and Chairman of the Board since founding MicroStrategy in 1989 and taking it public in 1998. Under Mr. Saylor's leadership, MicroStrategy has become a global leader in business intelligence, serving the largest most respected enterprises and government organizations in the world. It has also been a technology pioneer in the fields of relational, web, mobile, and cloud analytics. More recently, MicroStrategy became the first publicly traded company to adopt bitcoin, a revolutionary financial technology, as its primary treasury reserve asset. As Executive Chairman, Mr. Saylor will focus primarily on innovation and long-term corporate strategy, while continuing to provide oversight of the Company's bitcoin acquisition strategy as head of the Board's Investments Committee.

15:02 EDT American Electric reports completion of sale of Cardinal Plant Unit 1 - American Electric Power announced it has completed the sale of the 595-megawatt Cardinal Plant Unit 1 in Brilliant, Ohio, from AEP Generation Resources, the company's competitive generation affiliate, to Buckeye Power. "AEP Generation Resources will purchase 100% of Unit 1's output through a power purchase agreement through 2028. Cardinal Operating Company currently operates Cardinal Plant, and Buckeye already owns the other two units at the plant. Due to the competitive nature of the transaction, the sale price will not be disclosed. The sale of Cardinal Plant Unit 1 completes AEP Generation Resources' exit from competitive generation ownership in Ohio and reinforces AEP's focus on its regulated business operations and infrastructure," the company stated.

14:43 EDT Essential Utilities raises dividend 7% to 28.7c per share - The board of directors of Essential Utilities declared a quarterly cash dividend of 28.7c per share, payable Sept. 1 to all shareholders of record on Aug. 12. The Sept. 2022 dividend will represent a 7% increase compared to the 26.82c cash dividend the company paid in June of this year. Following the increase, the annualized dividend rate will be $1.1480 per share. The company's targeted dividend payout ratio continues to be 60 to 65% of net income. "Our long history of consecutive quarterly cash dividends demonstrates the company's commitment to delivering consistently strong results while also focusing on operational excellence, investment in infrastructure, protecting the environment, serving our customers and delivering value to our shareholders," said Essential Chairman and CEO Christopher Franklin. "The Board's decision to increase the quarterly dividend reflects continued confidence in the company's commitment to providing both safe and reliable access to natural resources and a strong total shareholder return profile."

14:21 EDT California AG announces $15.5M judgement against Rent-A-Center - California Attorney General Rob Bonta announced a $15.5M settlement against Rent-A-Center for violations of state consumer protection laws relating to unlawful leasing practices and deceptive marketing. As part of the stipulated judgment resolving the Attorney General's investigation, Rent-A-Center will be required to comply with significant injunctive terms to deter future misconduct, pay $13.5M in restitution to California consumers, and pay $2M in civil penalties. Reference Link

14:06 EDT WEC Energy says working toward goal of completely eliminating coal by 2035 - Comments taken from Q2 earnings conference call.

13:11 EDT CHW Acquisition Corp trading resumes

12:55 EDT SAI.TECH Global Corp trading resumes

12:50 EDT SAI.TECH Global Corp trading halted, volatility trading pause

12:19 EDT Magnolia Oil & Gas raises quarterly dividend to 10c per share - Magnolia Oil & Gas announced that its Board of Directors has declared a cash dividend of 10c per share of Class A common stock, and a cash distribution of 10c per Class B unit payable on September 1, 2022 to shareholders of record as of August 12, 2022. In addition, and beginning with this distribution, Magnolia will move to a quarterly dividend payment from a semi-annual distribution schedule. Today's announcement represents a 40c per share annualized rate or a 43 percent increase to Magnolia's dividend compared to the 28c per share distribution for full year 2021. Magnolia's next quarterly dividend is expected to be declared in November and paid in December.

12:15 EDT Honda reports July U.S. sales down 47.4% to 71,235 units - American Honda reports July sales of 71,235 units, down 47.4% year-over-year, stating that "strong retail demand continues despite supply chain and logistics constraints." Honda sales of electrified vehicles topped 6,500 units, led by CR-V Hybrid and Accord Hybrid, the company noted. Reference Link

12:01 EDT Enhabit falls -13.9% - Enhabit is down -13.9%, or -$2.49 to $15.48.

12:00 EDT Transocean rises 21.1% - Transocean is up 21.1%, or 68c to $3.90.

12:00 EDT AMTD IDEA Group rises 280.8% - AMTD IDEA Group is up 280.8%, or $5.84 to $7.92.

11:31 EDT Mazda Motor reports July U.S. sales down 28.5% to 23,393 vehicles - Mazda North American Operations reported total July sales of 23,393 vehicles, a decrease of 28.5% compared to July 2021. Year-to-date sales totaled 166,195 vehicles; a decrease of 25.1% compared to the same time last year. With 26 selling days in July, compared to 27 the year prior, the company posted a decrease of 25.8% on a daily selling rate basis.

11:07 EDT AC Immune announces presentation of data from API ADAD Colombia trial - AC Immune announced that its partners presented the first quantitative data from the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial during a Focused Topic Session at the Alzheimer's Association International Conference. The study evaluated the potential of the anti-amyloid beta antibody crenezumab to slow or prevent Alzheimer's disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer's disease. As previously reported on June 16, 2022, the trial did not meet its co-primary endpoints. Numerical differences favoring crenezumab over placebo were observed across both of these co-primary endpoints; statistical significance was not reached. Additional clinical and biomarker measures also showed numerical differences favoring crenezumab over placebo that did not reach statistical significance. Clinical endpoints showed the following relative changes in annualized scores compared to placebo, in all cases favoring crenezumab though in all cases not statistically significant: Cognitive test scores: API ADAD composite 22.9%; FCSRT 19.9%; RBANS total score 43.8%; Clinical/function: Time to MCI/dementia due to AD 20.8%; time to non-Zero in CDR-GS 8.1%; CDR Sum of Boxes 8.8%. Biomarker results also favored crenezumab with the following relative changes compared to placebo, all favoring crenezumab though not statistically significant: PET measures: Abeta PET SUVR 3.6%; Tau-PET SUVR 51.1%; FDG PET SUVR 18.1%; CSF measures: t-tau 28.7%; p-tau-181 37.4%; NfL 18.2%. The API ADAD trial enrolled 252 people who are members of the world's largest extended family with ADAD in Colombia. Two-thirds of participants carried the Presenilin 1 E280A mutation which typically causes cognitive impairment due to Alzheimer's disease around age 44. Approximately half of enrolled mutation carriers were negative for amyloid beta at enrolment. Participants were randomized to receive crenezumab or placebo for a planned duration of five to eight years. During the trial, the dose of crenezumab was increased more than seven-fold as knowledge about potential treatment approaches for Alzheimer's disease evolved. The average age of mutation carriers enrolled in the trial was 37.nLimitations of the API ADAD study noted in the AAIC presentation included limited statistical power to determine whether treatment with crenezumab at the optimal dose, which was received by most subjects for only about two out of five years, would have a clinical benefit. Demographic and baseline data indicate the study's lower-than-expected statistical power may have been due to a confluence of factors, including a study population that was on average younger and at an earlier preclinical Alzheimer's disease stage than expected.

11:02 EDT Live Nation's Ticketmaster announces multi-year partnership with XFL - The XFL and Ticketmaster, a part of Live Nation Entertainment, announced a new, multi-year partnership making Ticketmaster the Official Ticketing Partner of the XFL. All 43 games of the XFL season across the League's eight team markets will be ticketed by Ticketmaster, the company and league announced. "We are pleased to renew our partnership with Ticketmaster, an industry leader with advanced capabilities and global reach to deliver at the scale required by the XFL. Collaboration and innovation are two key values for the XFL, and in working with Ticketmaster we will ensure a seamless ticketing experience that will allow our fans to enjoy the XFL's exciting and dynamic football experience," said Russ Brandon, XFL President.

10:31 EDT L&F Acquisition Corp (Class A Stock) trading resumes

10:25 EDT Context Therapeutics announces clinical trial collaboration with Menarini Group - Context Therapeutics and The Menarini Group announced a clinical trial collaboration and supply agreement for Menarini's oral selective estrogen receptor degrader, or SERD, elacestrant. This agreement will support the upcoming Phase 1b/2 ELONA clinical proof-of-concept trial evaluating onapristone extended release, an oral progesterone receptor antagonist, in combination with elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context will sponsor the clinical trial and Menarini will supply elacestrant at no cost. Preliminary data from preclinical studies suggest that a dual ER and PR blockade may be associated with enhanced tumor control. The ELONA clinical trial will be evaluating this hypothesis. Context anticipates initiating the Phase 1b/2 clinical trial in the fourth quarter of 2022. The two companies will form a joint committee to review results. "We are grateful to Menarini for their collaboration as we explore the therapeutic potential of adding ONA-XR, our oral PR antagonist, to elacestrant," said Tarek Sahmoud, MBBCh, Ph.D., Context's Chief Medical Officer. "We hope that this combination will further improve the clinical outcome in patients with ER+, PR+, HER2- mBC."

10:24 EDT JetBlue embarking on new plan to keep costs low, says president

10:19 EDT JetBlue to phase out E190 fleet by mid-2025

10:06 EDT JetBlue beginning early work on Spirit integration planning, says CEO

10:04 EDT JetBlue CEO 'pleased we found a path forward' with Spirit

10:01 EDT Context Therapeutics, The Menarini Group partner on elacestrant - Context Therapeutics and The Menarini Group announced a clinical trial collaboration and supply agreement for Menarini's oral selective estrogen receptor degrader, elacestrant. This agreement will support the upcoming Phase 1b/2 ELONA clinical proof-of-concept trial evaluating onapristone extended release, an oral progesterone receptor antagonist, in combination with elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context will sponsor the clinical trial and Menarini will supply elacestrant at no cost. Context anticipates initiating the Phase 1b/2 clinical trial in the fourth quarter of 2022. The two companies will form a joint committee to review results.

10:01 EDT JetBlue sees return to profitability in 2H22

10:00 EDT TimkenSteel falls -13.0% - TimkenSteel is down -13.0%, or -$2.56 to $17.16.

10:00 EDT Emergent BioSolutions falls -16.4% - Emergent BioSolutions is down -16.4%, or -$5.61 to $28.62.

10:00 EDT Pinterest rises 14.8% - Pinterest is up 14.8%, or $2.96 to $22.95.

09:48 EDT Mobile Global Esports Inc trading resumes

09:47 EDT Arconic falls -8.3% - Arconic is down -8.3%, or -$2.51 to $27.91.

09:47 EDT Matson falls -9.7% - Matson is down -9.7%, or -$8.84 to $82.42.

09:47 EDT AMTD Digital rises 28.5% - AMTD Digital is up 28.5%, or $211.25 to $953.25.

09:43 EDT Mobile Global Esports Inc trading halted, volatility trading pause

09:40 EDT EJF Acquisition Corp trading resumes

09:38 EDT AMTD Digital Inc trading resumes

09:37 EDT Virax Biolabs Group Ltd trading resumes

09:35 EDT EJF Acquisition Corp trading halted, volatility trading pause

09:35 EDT GE Healthcare releases Definium 656 HD X-ray system - GE Healthcare released its most advanced fixed X-ray system yet, the next-generation Definium 656 HD. Leading GE Healthcare's portfolio of fixed X-ray products, this latest generation of the overhead tube suspension system delivers consistent, highly automated, efficient exams that impart clinical confidence while simplifying workflow, improving consistency, and reducing errors to help keep radiology departments running smoothly.

09:34 EDT Kaplan, Amazon partner for career, student support services - Kaplan (GHC) announced that it is partnering with Amazon (AMZN) to make comprehensive career and academic advisement support services available to the 750,000 hourly Amazon employees in the United States. Kaplan's partnership supports Amazon's Career Choice upskilling program, designed to help Amazon employees grow their skills for career success. The Kaplan-provided services will be available to Amazon employees through every step of their higher education journey, from first helping them identify the academic programs that best fit their interests, skills, and long-term goals to general support throughout their higher education experience to networking, resume development, job interview preparation, and online brand building.

09:32 EDT Woodward trading halted, volatility trading pause

09:32 EDT Virax Biolabs Group Ltd trading halted, volatility trading pause

09:31 EDT Pegasystems names Dr. Kikelomo Belizaire as Chief Medical Officer - Pegasystems (PEGA) announced the appointment of Dr. Kikelomo Belizaire as its first chief medical officer. With a strong clinical background and a passion for improving care outcomes, Dr. Belizaire will bring a clinical lens to Pega's strategy for serving its healthcare clients. Dr. Belizaire most recently served as a medical director in the commercial business unit at Anthem (ELV), where she focused on medical management services for company health plans and clinical integrity of programs.

09:29 EDT Summit Therapeutics right offering nearing expiration date - Summit Therapeutics announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time on August 8, 2022. Importantly, for stockholders whose shares of our common stock are held in a brokerage account or are otherwise not registered directly with the Company, the deadline to exercise their subscription rights with their respective brokerage firms may be earlier. Information regarding specific broker-related deadlines should be obtained directly from the broker. As a reminder with respect to the rights offering, the aggregate offering value is up to $100 million. The subscription rights will expire and have no value if they are not exercised prior to the Expiration Date. The subscription price per share shall be equal to the lesser of $1.08 per share or the volume weighted-average price of the Company's common stock for the five consecutive trading days through and including the Expiration Date. The subscription price per share will determine the final number of shares issuable, and subsequently the pro rata number of Shares to which stockholders can subscribe. As an update to the Company's current financial position, Company's aggregate cash, accounts receivable, and tax credits receivable as of June 30, 2022 totaled at least $73 million (unaudited). The Company believes that it has the ability to fund its operating costs and anticipated working capital needs into the third quarter of 2023.

09:28 EDT Eaton Partners acts as placement agent for Assured Healthcare Partners - Eaton Partners is pleased to have acted as placement agent for Assured Healthcare Partners, a New York-based healthcare services firm focused on creating shared value through active and high influence investments in U.S. healthcare companies. AHP Fund II exceeded its initial cap of $750 million of capital commitments, surpassing its target of $650 million. Fund II received support from existing investors and several new limited partners, comprising a diverse set of global institutional investors, including pension plans, insurance companies, funds of funds, endowments, foundations, and family offices.

09:14 EDT Elevance Health, Aledade team on consumer experience for primary care practices - Elevance Health and Aledade announced a partnership that will help enhance the consumer experience and health outcomes for those seeking services from independent primary care practices. The partnership centers on assisting independent primary care physicians across the country transition to value-based care, which is proven to improve health outcomes and lower costs for consumers. Independent primary care providers participating in Elevance Health's affiliated plans' networks - which serve 47 million members - now have the opportunity to access Aledade's unique suite of technology and local, in-person services. These offerings give independent primary care practices the enhanced tools, support, and resources they need to make the transition to value while delivering the best care to their patients. "Healthcare reimbursement based on outcomes instead of quantity of services has been debated for decades. Too often, primary care providers want to make this transition but struggle," said Bryony Winn, President of Health Solutions at Elevance Health. "Partnering with Aledade empowers our independent care provider partners with the tools and insights they need to provide higher quality, more affordable care, while succeeding financially."

09:10 EDT Waitr partners with New Orleans Saints for in-stadium mobile ordering - Waitr Holdings announced a partnership with the with the New Orleans Saints to bring in-stadium ordering to the Caesars Superdome in New Orleans. Fans, in select sections, will be able order food and beverages right from their phones using the new ASAP app for all Saints home games. The deal with the Saints is the latest high-profile agreement Waitr, soon to be ASAP, has secured with teams from the National Football League. Just last week, the delivery and payments technology company partnered for stadium service with the New York Jets and New York Giants. The mobile ordering experience for Saints games also serves as an introduction of the new ASAP brand name for New Orleans, which was among the first cities served when Waitr was originally launched in Louisiana in 2015. "We're excited to provide this unique stadium experience for some of the best fans in the NFL," said Carl Grimstad, CEO and Chairman of Waitr Holdings Inc. "Our proprietary in-stadium ordering technology provides what we consider an essential service, because it allows Saints fans to skip the concession lines and pick up their order without missing any of the game action."

09:09 EDT Eguana receives follow on order of over $2.4M to be deployed in Hawaii - Eguana Technologies (EGTYF) announced it has received follow on orders of over $2.4M in units to be deployed in Hawaii's VPP Battery Bonus program this year. Eguana's partner Pineapple Energy (PEGY), who recently acquired Hawaii Energy Connection, is one of the leading installers for the Battery Bonus program. The Battery Bonus program was established to address a gap in peaking capacity on the island of Oahu, driven by the scheduled retirement of the island's only coal facility, by using a fleet of residential home energy storage systems charged with solar power. The program launched mid-2021 with the first phase targeting retrofits to existing solar systems installed under the original NEM tariff program. Battery Bonus program rules have now been modified to encourage faster uptake by compensating system owners under the island's popular CGS and CGS+ tariffs. The changes will make the program attractive for most solar homeowners and is expected to accelerate installations in 2022 and beyond. "Recent program modifications are expected to accelerate installations in the short term as more residential solar homeowners participate," added Eguana CEO Justin Holland. "The Pineapple Energy team in Hawaii is intimately familiar with the Eguana Evolve and we look forward to increasing shipments for the battery bonus program as well as expansion into mainland opportunities with the Pineapple Energy team."

09:08 EDT Sidus Space selects AWS for LizzieSatTM Constellation - Sidus Space (SIDU) announces its selection of Amazon (AMZN) Web Services to provide cloud storage of mission critical Satellite-as-a-Service operation and customer data for the upcoming LizzieSat Constellation. The primary mission of LizzieSat is to enhance the collection and intelligent analysis of customers' space-born data returning richer, more precise data down to Earth in less time. By leveraging AWS-managed services like Amazon Elastic Compute Cloud , Amazon Elastic Container Service , and Amazon Simple Storage Service , Sidus Space aims to provide reliable, global mission control operations to its customers. AWS provides robust, secure, and near real-time data access that enables Sidus to more rapidly and efficiently manage the large volumes of mission data produced by its constellation of satellites and enhance customer data with on platform analytics and secure access points via infrastructure as a service customization. AWS seamlessly aligns with KSAT, Sidus Space's ground station provider, and provides a cost-effective solution to enhance Sidus Space's Space-as-a-Service data offerings for its diverse customer base.

09:06 EDT EnWave announces retirement of Ritchie from board of directors - EnWave Corporation announced that Dr. Stewart Ritchie, a globally recognized expert in poultry science, has retired from the Company's Board of Directors. Dr. Ritchie made the decision to step down due to personal health reasons. The Company does not plan to fill the vacancy created by the departure of Dr. Ritchie. EnWave's Board of Directors currently sits at six members, four of which are independent.

09:05 EDT Tetra Tech wins $500M contract for environmental remediation services - Tetra Tech announced that the U.S. Army Corps of Engineers, USACE, Engineering and Support Center, Huntsville , selected the Company to provide comprehensive environmental remediation services to the Department of Defense outside the continental United States,OCONUS. The value of the indefinite delivery, indefinite quantity, multiple-award International Remediation and Environmental Services contract is $500M. Tetra Tech will work with the Huntsville Center to safely identify, recover, and remediate hazardous, toxic, and radiological waste at OCONUS sites. Tetra Tech's scientists, engineers, and geophysicists will provide technical services to address human health and environmental risks using real-time field data collection and web-accessible GIS visualization to support engineering evaluations, sampling and analysis, and remedial or removal actions. "Tetra Tech has supported the U.S. Army's environmental clean-up programs for more than two decades," said Dan Batrack, Tetra Tech Chairman and CEO. "We are pleased to continue using our Leading with Science approach to support the USACE Huntsville Center as it works to restore lands and waters to safe and productive use and improve lives in communities around the world."

09:04 EDT Synovus appoints Shellie Creson as chief risk officer - Synovus announced the appointment of Shellie Creson as its chief risk officer. She succeeds Mark Holladay who retired from Synovus in March. Creson reports to president and CEO Kevin Blair and joins the Synovus executive leadership team. She leads the company's corporate risk management strategy, continuing to transform, strengthen and sustain its strong risk culture. Creson is based in Atlanta, Georgia. Prior to Synovus, Creson served as executive vice president and chief audit executive at Fifth Third Bank, where she provided strategic, proactive leadership and oversight of all audit activities conducted across the company.

09:02 EDT Nuvei enters partnership with Selina - Nuvei Corporation announces that it has partnered with Selina, the fast-growing experiential hospitality brand targeting the remote worker and digital nomad. Nuvei is Selina's payments provider offering local card acquiring services in Europe and Israel, and soon also in multiple territories including the US, Latin America and Australia. The addition of alternative payment methods is also on the roadmap for delivery in 2022. Commenting on the payments collaboration, Nuvei Chair and CEO Phil Fayer said: "We're experiencing first-hand how the Millennial and Gen Z population are redefining what good looks like when it comes to payments across a variety of key verticals. We're thrilled to work with Selina to bring the future of payments to their tech savvy customers, today." Nir added: "We expect to continue to benefit from the surge in remote working and the prioritization of health, wellness, and an experiential lifestyle among Millennial and Gen Z travelers, which means growth is firmly on the agenda. To achieve our plans, we need a payment partner to help power our growth and we have full confidence that Nuvei is the partner for us."

09:01 EDT Freddie Mac announces tender offer for STACR debt notes - Freddie Mac announced that it has commenced a fixed-price cash tender offer for the purchase of any and all of the STACR debt notes beginning Tuesday, August 2, 2022. Freddie Mac has engaged BofA Securities, Inc. and Wells Fargo Securities, LLC as lead dealer managers and Academy Securities, Inc. as co-dealer manager for the Offer. Freddie Mac is offering to purchase any and all of the Notes listed in the table below. The applicable Total Consideration to be paid by Freddie Mac to holders that tender Notes accepted for purchase pursuant to the Offer will be calculated based on the original principal amount of such tendered and accepted Notes, the applicable factor, and the applicable Tender Offer Consideration identified in the table below, plus any accrued and unpaid interest under the applicable debt agreement upon the terms and subject to the conditions set forth in the Offer to Purchase dated August 2, 2022 and related Notice of Guaranteed Delivery dated August 2, 2022. Capitalized terms used and not otherwise defined herein will have the meaning ascribed to such terms in the Offer to Purchase. The tender offer period will commence on Tuesday, August 2, 2022, and expire at 5 p.m. New York City time on Monday, August 8, 2022, unless extended. Holders must validly tender their Notes at or prior to the Expiration Time. Notes validly tendered may be withdrawn at any time at or prior to 5 p.m., New York City time, on Monday, August 8, 2022, unless extended by Freddie Mac, but not thereafter. Holders whose Notes are purchased in the Offer will receive accrued and unpaid interest from the last interest payment date to, but not including, the Settlement Date for the Notes. Freddie Mac expects the Settlement Date to occur on Wednesday, August 10, 2022. Any Notes tendered using the Notice of Guaranteed Delivery and accepted for purchase are expected to be purchased on Thursday, August 11, 2022, but payment of accrued interest on such Notes will only be made to, but not including, the Settlement Date.

08:54 EDT Vivakor closes acquisitions of Silver Fuels Delhi, White Claw Colorado City - Vivakor announced it has closed on the acquisitions of Silver Fuels Delhi and White Claw Colorado City pursuant to the previously announced June 15, 2022 Membership Interest Purchase Agreement among the Company, Jorgan Development and JBAH. Total consideration paid for SFD and WCCC was $37.4 million consisting of shares of restricted common stock equal to 19.99% of the total issued and outstanding shares of Vivakor's common stock that are subject to lock-up agreements preventing their sale for a period of up to 18 months, promissory notes and certain assumed liabilities which are subject to post-closing adjustments. SFD owns and operates a crude oil gathering, storage, and transportation facility located on approximately 9.3 acres near Delhi, Louisiana. For a period of 10 years, SFD is, under existing crude oil supply agreements with White Claw Crude, LLC, guaranteed a minimum gross margin under a take or pay contract. At present, SF Delhi is gathering approximately 1,400 to 1,700 barrels of crude oil on a daily basis. WCCC owns a 120,000 barrel oil tanking facility, in the heart of the Permian Basin, located near Colorado City, Texas. The tanking facility is presently connected to the Lotus pipeline system and Vivakor intends to further connect the tanking facility to additional pipeline systems. Under the terms of an already existing agreement, White Claw Crude, LLC has agreed to lease the oil storage tank for a period of 10 years. As with SF Delhi, WCCC would provide Vivakor with the infrastructure to blend and sell oil which has been recovered via Vivakor's Remediation Processing Center machine from tank bottom sludge and contaminated soil which exists in the Permian Basin. SFD and WCCC generated approximately $33 million of aggregate revenue and positive Earnings before Interest, Taxes, Depreciation, and Amortization during 2021.

08:52 EDT Winners enters LOI to acquire 'The Longshot Report' - Winners, Inc. executed a letter of intent to acquire Golf Longshots, LLC., known as The Longshot Report, a rapidly growing internet/online subscription-based company that gives daily and weekly advice on a broad range of sports picks for fantasy and sports betting with an online platform and mobile app available for download at the App Store and Play Store. The acquisition is scheduled to close early this month. The Longshot Report, founded in 2019 has seen dramatic Annual Revenue growth since inception with over 15,000 active subscribers, digital infrastructure in place, web platform, mobile app, payment processing center, developed App available for download in the App Store and Play Store and a guide to "Beating the Sports Betting Market" available on its website.

08:49 EDT Xenetic, VolitionRx collaborate to develop NETs-targeted adoptive cell therapies - Xenetic Biosciences (XBIO) and VolitionRx Limited (VNRX) announced a research and development collaboration to develop Neutrophil Extracellular Traps targeted, adoptive cell therapies for the treatment of cancer. The collaboration is an early exploratory program to evaluate the potential combination of Volition's Nu.Q NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers. Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration.

08:46 EDT Caterpillar says Q2 sales 'broadly in-line with expectations' - Says Q2 topline would have been stronger if not for supply chain constraints. Says orders "remain solid." Expects sales growth in 2H22 both sequentially and y/y. Says dealer inventory remains near "low end of typical range." Expects prices to offset inflation through 2H22. Comments taken from Q2 earnings conference call.

08:37 EDT Sysco donates $1M to Feeding America - Sysco Corporation announced it recently donated $1M to Feeding America to support local food banks in communities where Sysco operates. Sysco's donation will be distributed to 42 food banks across the U.S. as part of their signature Nourishing Neighbors program where a portion of the proceeds from each Sysco branded case sold in local communities is donated back to charitable organizations in those communities.

08:36 EDT ABVC BioPharma provides Vitargus update - ABVC BioPharma announced that the Ethics Committee of Srinagarind Hospital, Khon Kaen University of Thailand approved the Vitargus Phase II Clinical Study Protocol. Srinagarind is one of two sites in Thailand that have agreed to participate in the study. The other site, Ramathibodi Hospital, Mahidol University, expects to receive EC approval in the near future. It is anticipated that a total of 20 or more patients undergoing vitreo-retinal surgery will be included in the studies at the selected sites. The final step prior to initiating the two studies is the issuance of an EC investigational product import license by the Food and Drug Administration of Thailand. In addition, Vitargus Phase II Clinical Study protocol documents are now under review by the Australian Bellberry Human Research Ethics Committee. Upon approval, a Clinical Trial Notification of the study will be issued leading to a final review by the Australian Therapeutic Goods Administration. Upon TGA approval, the clinical trial will begin in Australia at the previously selected sites. "We are pleased to receive quick EC approval of the Vitargus Phase II study by Srinagarind Hospital, Khon Kaen University of Thailand," said Dr. Howard Doong, Chief Executive Officer of the Company. "These two prestigious Thai clinical sites, plus the originally-planned Australia sites, are key to reaching our overall enrollment goals for the Phase II study of Vitargus."

08:35 EDT Agilent acquires Polymer Standards Service, terms undisclosed - Agilent announced it has acquired Polymer Standards Service, or PSS, a provider of solutions in the field of polymer characterization. PSS specializes in hardware and software solutions used in defining the makeup and creation of molecular structures. The company provides complete solutions for gel permeation chromatography and size exclusion chromatography used in applications to determine the molecular weight and size distribution of macromolecules. The acquisition broadens and extends Agilent's product portfolio and customer offerings, particularly in the chemical and biopharmaceutical industries for the analysis of natural and synthetic polymers such as nucleic acids, proteins, monoclonal antibodies, polysaccharides, and synthetic plastic. By acquiring PSS, Agilent will also add a software component to complement its lineup of GPC/SEC products. In addition, Agilent will be able to use its global presence to expand the use of PSS products and expertise more widely. Agilent customers in the chemical, biopharmaceutical and other key segments will now also be able to take advantage of PSS technology more broadly because of Agilent's strong global presence in those markets. Founded in 1985, PSS is privately held and is based in Mainz, Germany, with additional operations in Amherst, Massachusetts. Financial terms of Agilent's acquisition of PSS were not disclosed.

08:34 EDT Canopy Growth appoints Christelle Gedeon as Chief Legal Officer - Canopy Growth (CGC) announced that the appointment of Christelle Gedeon, as the Company's new Chief Legal Officer. Named one of Canada's Law Department Leaders of the Year and listed on the Legal 500 GC Powerlist in 2020, and the 2019 Canadian General Counsel Awards Tomorrow's Leader, Christelle is an accomplished commercial lawyer and strategist with more than a decade of legal and strategic experience including most recently as the Chief Legal Officer and Corporate Secretary for The Metals Company (TMC). Prior to this, she served as the Chief Legal Officer and Corporate Secretary at Aphria, where she oversaw the reverse takeover of Tilray. Her appointment to the role of Chief Legal Officer at Canopy Growth is effective immediately.

08:33 EDT International General Insurance to acquire Energy Insurance Oslo - International General Insurance announced that it has signed a non-binding letter of intent to acquire Energy Insurance Oslo, or EIO, a managing general agency duly incorporated under the laws of Norway. The proposed transaction includes the acquisition of 100% of EIO's shares. Pending satisfactory completion of due diligence and subject to regulatory approval, IGI and EIO intend to enter into a binding definitive agreement. Upon completion of the acquisition, IGI expects that EIO will be renamed International General Insurance Company and will become a wholly-owned subsidiary of Bermuda-based International General Insurance. The transaction is expected to close in Q3, subject to regulatory approvals.

08:33 EDT Grove announces Upexi signs non-binding LOI to acquire E-Core - Upexi, wholly owned division of Grove, has signed a non-binding LOI to acquire E-Core and its brand subsidiaries, including New England Technology, and Tytan Tiles. The diversified business fits perfectly with the company's brand acquisition strategy and its recently acquired, Cygnet Online business. NETi has seen growth over the previous year with $35+ million in TTM revenues and represents a significant increase to Grove's current run rate and forecast. Grove plans to fund this acquisition without an additional equity offering. The shareholder-friendly structured deal uses debt, restricted equity, and payouts in subsequent years based on revenue and EBITDA milestones. CEO Allan Marshall commented, "Successfully closing this acquisition should put us on target for accelerating revenue and EBITDA in 2023 above our previously announced estimates. Synergies between NETi and our current business will provide scale and additional growth opportunities. The name change is part of our expanding business and the exciting opportunities we have in the pipeline." Grove and E-Core anticipate that the transaction will close in August 2022.

08:27 EDT WSP Global to acquire Capita's Capita REI, GL Hearn businesses for GBP 60M - WSP Global has entered into an agreement to acquire two UK-based businesses: Capita Real Estate and Infrastructure and GL Hearn both owned by Capita plc. for an aggregate cash consideration of GBP 60 million. The transaction is expected to close upon receipt of regulatory approvals and within approximately six to eight weeks. Capita REI is a leading provider of specialist advisory, design, engineering, environmental and project management services for land, building and infrastructure owners, while GLH provides cross-sector advice to developers and investors. Together, both businesses will add around 1,000 UK-based employees to WSP's workforce, reinforcing its existing service offering within the country and expanding its strategic advisory offering.

08:25 EDT Fulcrum Therapeutics reports inducement of grants - Fulcrum Therapeutics announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company's 2019 Stock Incentive Plan. Fulcrum granted stock options to purchase an aggregate of 162,700 shares of the Company's common stock to four new employees. The awards were granted as of August 1, 2022, pursuant to the Company's 2022 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Fulcrum Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

08:24 EDT Microchip announces SMC 2000 series of CXL based Smart Memory Controllers - Microchip Technology announces the expansion of its serial-attached memory controller portfolio with the new SMC 2000 series of Compute Express Link based Smart Memory Controllers that enable CPUs, GPUs and SoCs to utilize CXL interfaces to connect either DDR4 or DDR5 memory. This solution delivers more memory bandwidth per core, more memory capacity per core, and lowers the overall total cost of ownership in the data center by allowing modern CPUs to optimize application workloads.

08:22 EDT Satsuma completes enrollment in SUMMIT Phase 3 trial of STS101 - Satsuma Pharmaceuticals announced completion of subject enrollment in the Company's ongoing STS101 SUMMIT pivotal Phase 3 efficacy trial, with more than 1,400 subjects randomized. Satsuma expects to announce topline results from the SUMMIT trial in the fourth quarter of 2022. "We are pleased to report completion of subject enrollment in the STS101 SUMMIT Phase 3 efficacy trial, the largest-ever randomized and controlled trial of a DHE product," stated John Kollins, Satsuma's President and Chief Executive Officer. "This marks an important milestone in our STS101 development program. We look forward to reporting SUMMIT trial topline results in the fourth quarter of 2022, and, in the interim, to reporting further STS101 development program progress and clinical data, including topline results from our ongoing STS101 ASCEND Phase 3, open-label, long-term safety trial."

08:19 EDT Uber One subscription reached 10M members, says CEO

08:19 EDT Uber CEO: New driver sign-ups up 76% in Q2 vs. 2021

08:18 EDT Lincoln Educational signs agreement with Tesla - Lincoln Educational Services (LINC) has signed a new agreement with Tesla (TSLA). A Tesla training facility will be established at Lincoln Tech's Denver, CO campus as part of a 3-year plan whereby the school will provide Tesla START training at no cost to students to help develop the next generation of Tesla's service technician workforce. Automotive Technology graduates from any of Lincoln Tech's campuses will be eligible to apply for this advanced EV training program. "Entering into this agreement with Tesla solidifies Lincoln Tech's commitment to providing electric vehicle training for 21st century Automotive Technicians," says Scott Shaw, Lincoln Tech's President and CEO. "It is the latest advancement in our EV training programs, and having Tesla's backing and input in developing these programs will be invaluable for our organization and for our students. It is our intention to become the leading provider of EV Automotive Technology training," Shaw adds. Students accepted into the 16-week program will receive an hourly stipend while they train. The Tesla training facility will occupy approximately 6,000 square feet of space in Lincoln Tech's Denver campus. Lincoln will provide logistical support for the capstone program, including aiding Tesla in recruiting technicians looking to further their skills on Electric Vehicle systems. The potential to expand to additional Lincoln campuses is also being considered as Tesla faces the need for skilled technicians across North America.

08:15 EDT Applied DNA begins validation of PCR-based monkeypox virus test - Applied DNA Sciences announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, has initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus. The test has been developed as a type of NYSDOH Laboratory Developed Test . If the test is validated by ADCL, a validation package will be submitted to New York State Department of Health for approval. If approved, the test will be used to power ADCL's monkeypox testing services. ADCL's monkeypox test utilizes an A17L gene-target specific to monkeypox that enables the qualitative detection and differentiation of monkeypox virus from other non-variola orthopoxviruses using real-time PCR. If validated and approved, testing will be performed at ADCL's CLEP/CLIA molecular diagnostics laboratory in Stony Brook, N.Y., utilizing its established and proven workflows to ensure accurate results and competitive turn-around-times. "Based on our experience with the COVID-19 pandemic, we are keenly aware of the crucial role PCR-based diagnostic tools can play in responding and helping to control public health outbreaks. With a proven workflow and testing services born of COVID-19, upon test approval, ADCL stands ready to apply its testing capacity in service of New Yorkers' health," stated Dr. James A. Hayward, president and CEO of Applied DNA Sciences.

08:14 EDT Netreo signs Arrow Electronics as distributor - Netreo announced a formal agreement with Arrow Electronics. The relationship supports Netreo's conversion to exclusive channel sales with the resources of the Arrow Enterprise Computing Solutions division supporting Netreo's growing list of global resellers.

08:12 EDT C4 Therapeutics appoints Bessen, Grogan to board of directors - C4 Therapeutics announced the appointments of Laura Bessen, M.D. and Donna Grogan, M.D. to its board of directors. Laura Bessen, M.D. currently serves as managing partner at Maxsam Advisors LLC where she provides strategic clinical and medical affairs advice. Donna Grogan, M.D. currently serves as Principal of Grogan Consulting.

08:11 EDT VBL Therapeutics to reduce workforce by 35% - VBL Therapeutics announced an organizational streamlining designed to reduce operating expenses and preserve capital. As a result, VBL will reduce its workforce by approximately 35%. As part of the cost cutting initiatives, Dr. Ron Cohen, Dr. Bennett Shapiro and Ms. Alison Finger resigned from the board of directors, effective August 1, 2022. VBL estimates that it currently has sufficient cash on hand to fund planned operations for at least the next 12 months.

08:10 EDT Caladrius completes enrollment in Phase 1b study of CLBS201 - Caladrius Biosciences announced the completion of enrollment and dosing in its Phase 1b, open-label, proof-of-concept study of CLBS201, a CD34+ regenerative cell therapy investigational product for intra-renal artery administration, for the treatment of diabetic kidney disease. The Company expects to announce top-line data from all subjects by the first quarter of 2023.

08:07 EDT Great Lakes Dredge does not expect to meet full year expectations - Lasse Petterson, President and Chief Executive Officer commented, "As we enter the third quarter, we expect results for the second half of 2022 to be stronger than the first, however due to the issues encountered in the first half of the year, we do not anticipate meeting full year expectations."

08:06 EDT Phathom Pharmaceuticals expects cash to fund operations through 2024 - As of June 30, 2022, cash and cash equivalents were $207.4 million plus an additional $100 million in liquidity available under its term loan with Hercules Capital.Based on its current operating plan, and the anticipated funds available under the existing term loan and royalty interest finance agreements, the Company believes it has sufficient capital to fund operations through 2024.

07:49 EDT Amesite expands partnership with WSU - Amesite announces the expansion of its partnership with Wayne State University, WSU, and its College of Engineering with the integration of its V5 eCommerce solution. Learners will now experience a streamlined process to register, pay, and onboard courses directly from the Wayne State University Warrior Tech Source website. "This expansion is another exciting win for Amesite," said Dr. Ann Marie Sastry, Founder & CEO of Amesite. "Our V5 capabilities are what the market needs, and we are thrilled to be able to equip our Partners with the technology solutions and services they need to scale globally. Instead of competing universities against one another, or simply creating products that we push-market under their names, we are helping them genuinely meet their missions by delivering programs that work for their learners. The market size is enormous, because there are thousands and thousands of universities that need this solution, and we are proud to partner with them and deliver learning with excellence."

07:46 EDT Algoma Steel announces final results of substantial issuer bid - Algoma Steel Group announced the final results of its substantial issuer bid under which it has purchased for cancellation 41,025,641 of its common shares at a purchase price of US$9.75 per Share, for an aggregate purchase price of approximately US$400 million. Shares purchased under the Offer represent approximately 27.9% of the issued and outstanding Shares at the time that the Offer was commenced. Immediately following completion of the Offer on July 27, 2022, 105,403,930 Shares were issued and outstanding. Based on the final count by TSX Trust Company, the depositary for the Offer, a total of 60,835,820 Shares were properly tendered and not withdrawn. As the Offer was oversubscribed, shareholders who made auction tenders at a price of US$9.75 or less per Share and purchase price tenders will have approximately 94.68% of their successfully tendered Shares purchased by Algoma. Shareholders who made auction tenders at a price in excess of US$9.75 per Share will have their Shares returned by the Depositary. Payment for the Shares accepted for purchase under the Offer will occur in accordance with the terms of the Offer and applicable law. The Corporation expects to be eligible to recommence purchases under its normal course issuer bid after all Shares accepted for purchase under the Offer have been taken up. To assist shareholders in determining the Canadian tax consequences of the Offer, Algoma estimates that for the purposes of the Income Tax Act, the paid-up capital per Share is approximately C$5.43. Given that the purchase price of US$9.75 per Share exceeds the paid-up capital per Share, shareholders who have sold Shares to Algoma under the Offer will be deemed to have received a taxable dividend as a result of such sale for Canadian federal income tax purposes. The dividend deemed to have been paid by Algoma to Canadian resident persons is designated as an "eligible dividend" for purposes of the Income Tax Act and any corresponding provincial and territorial tax legislation. The "specified amount" for purposes of subsection 191(4) of the Income Tax Act (Canada) is US$9.42. Shareholders should consult with their own tax advisors with respect to the income tax consequences of the disposition of their Shares under the Offer.

07:44 EDT Patriot One Technologies secures deal with auto manufacturer - Patriot One Technologies announced it has secured a deal with a large U.S.-based auto manufacturer to protect all employee entrances at three of its manufacturing facilities. The auto manufacturer will use Patriot One's SmartGateway patron screening solution to unobtrusively scan all employees and workers for guns, knives and other weapons upon entrance to the facility. This not only provides a higher degree of safety for workers than traditional walk-through metal detectors but enhances the effectiveness and productivity of the manufacturing facility.

07:43 EDT Context Therapeutics, The Menarini Group announce clinical trial collab - Context Therapeutics and The Menarini Group announced a clinical trial collaboration and supply agreement for Menarini's oral selective estrogen receptor degrader, SERD, elacestrant. This agreement will support the upcoming Phase 1b/2 ELONA clinical proof-of-concept trial evaluating onapristone extended release, an oral progesterone receptor antagonist, in combination with elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context will sponsor the clinical trial and Menarini will supply elacestrant at no cost. Preliminary data from preclinical studies suggest that a dual ER and PR blockade may be associated with enhanced tumor control. The ELONA clinical trial will be evaluating this important hypothesis. "We are grateful to Menarini for their collaboration as we explore the therapeutic potential of adding ONA-XR, our oral PR antagonist, to elacestrant," said Tarek Sahmoud, MBBCh, Ph.D., Context's Chief Medical Officer. "We hope that this combination will further improve the clinical outcome in patients with ER+, PR+, HER2- mBC." Context anticipates initiating the Phase 1b/2 clinical trial in the fourth quarter of 2022. The two companies will form a joint committee to review results.

07:41 EDT Reneo Pharmaceuticals appoints Roshawn Blunt to board of directors - Reneo Pharmaceuticals announced the appointment of Roshawn Blunt to the company's Board of Directors. She is the President of Corsaire Corporation, a pharmaceutical commercialization organization.

07:38 EDT Versus Systems completes activation for Finastra - Versus Systems announced that Versus recently completed a activation for Finastra, marking the first XEO platform activation in the Corporate Meeting and Events segment. With this activation, Versus was able to leverage its deep experience with sports-based fan engagement to expand the market for Versus' leading audience engagement technology to a wider pool of potential clients. Considering the positive response of the Finastra event's attendees to the XEO platform, Versus anticipates it will be able to expand its activations in the Corporate Meeting and Events segment in the future.

07:35 EDT Thryv and Google team to streamline communication for small businesses - Thryv Holdings (THRY) announces a new integration with Google's (GOOG) Business Messages to help streamline communication for small businesses who have a growing number of inbound contact options. Thryv is a partner of Google's Business Messages, a mobile conversational channel that combines entry points on Google Maps, Search and brand websites to create rich, asynchronous messaging experiences that customers find easily accessible and drive business results. Google's Business Messages integrates within Thryv's real-time, centralized inbox, which launched last year and allows businesses to have a single thread of communication rather than relying on pockets of data located in individual applications. "Rapid expansion of communication technologies has helped usher in a new era of communication when it comes to customer service for businesses," said Ryan Cantor, Chief Product Officer at Thryv. "But only businesses with robust customer service teams and constant availability are benefiting from these advances. Local, service-based businesses, like a local roofing company, may not be able to respond to web chat messages quickly enough for customer satisfaction because they're on the roof. Thryv's integration with Google's Business Messages helps small businesses benefit from said advancements too. These local businesses don't have to decide between losing revenue and running their business . The 2020s will continue to be about small business cloud adoption, and we will be there along the way with product updates to support our small business customers."

07:33 EDT PSEG to invest $511M through Infrastructure Advancement Program - Ralph Izzo, chair, president and CEO said, "Results for the second quarter and the first half of 2022 reflect ongoing rate base growth from regulated investments and favorable cost comparisons resulting from the sale of PSEG Fossil, placing us on track to achieve our 2022 financial goals. We remain focused on improving system reliability, further de-risking the business overall, and maximizing affordability for our customers." Izzo continued, "As I step down from my CEO duties on September 1, PSEG is well positioned to enter its 120th year of serving New Jersey with essential energy services that help to power the economic engine of the State and advance its energy policy leadership. In my role as executive chair of the board through the end of 2022, I will continue to advocate on behalf of PSEG in key policy arenas. With Ralph LaRossa at the helm, PSEG will further advance its Powering Progress vision of a future where people use less energy, and it's cleaner, safer and delivered more reliably than ever. PSEG's dedicated workforce will continue the public service heritage that recently earned us the 2022 EEI Edison Award, the electric utility industry's highest honor, in recognition of PSE&G's infrastructure modernization programs focused on protecting our customers and communities from extreme weather conditions. The June 2022 approval of a four-year, $511 million investment in our Infrastructure Advancement Program will extend these reliability improvements to the "Last Mile" of our distribution system, as we prepare the grid for the rapid transition to electric vehicles and enable a greater blend of renewable energy resources."

07:30 EDT PSEG reports Q2 adjusted EPS 64c, consensus 65c - Reports Q2 revenue $2.08B, consensus $1.82B.

07:29 EDT Gilat Satellite signs agreement to provide digital services in Central Asia - Gilat Satellite Networks announced the Company signed an agreement to provide a SkyEdge II-c hub and hundreds of VSATs to a government in Central Asia. The Gilat equipment will be used to connect rural villages to the government network, serve as a backup communication channel for disaster preparedness, and provide remote services to citizens. "Gilat technology is being leveraged to connect people and provide for the efficient provisioning of services, regardless of geographic distances," said Michal Aharonov, Chief Commercial Officer at Gilat. "Once again, Gilat's SkyEdge II-c platform is bridging the digital divide and helping to improve the lives of people throughout the world."

07:28 EDT Pasithea Therapeutics urges stockholders to reject Camac Group's campaign - Pasithea Therapeutics announced that it has filed its definitive consent revocation statement with the U.S. Securities and Exchange Commission and sent a letter to Pasithea stockholders. The letter outlines Pasithea's response to the consent solicitation to call a Special Meeting of Stockholders by Camac Partners, Camac Capital, Concord IP2, Elderhill Corporation, Leonite Capital, Eric Shahinian, David Delaney, and Avi Geller. "The Board of Directors of Pasithea unanimously urges stockholders to reject what it believes is the Camac Group's misguided and self-serving attempt to undermine the Company's progress and destroy its meaningful upside potential. Pasithea urges its stockholders to sign, date, and return Pasithea's GOLD consent revocation card and discard any white consent solicitation card received from the Camac Group," the company said. The letter said: "Your Board believes the Camac Group appears to be attempting to co-opt the Company's cash and eliminate significant upside potential as we continue our activities to develop potentially groundbreaking therapies for psychiatric and neurological diseases with enormous unmet needs, such as multiple sclerosis and amyotrophic lateral sclerosis. The Camac Group's public commentary and proxy materials demonstrate a concerning ignorance of early-stage biotechnology companies, suggesting its sole objective is to take control of the Company and possibly liquidate Pasithea less than a year after the company's initial public offering... Your Board unanimously urges you to reject the Camac Group's short-sighted campaign by signing, dating and returning the GOLD consent revocation card and discarding any further materials and white consent cards you receive from the Camac Group... Your Board strongly urges you to reject the Camac Group's campaign by signing, dating and returning the enclosed GOLD proxy card to revoke any written consent card you may have previously returned to the Camac Group. DO NOT RETURN ANY WHITE CONSENT CARD you may have received from the Camac Group."

07:26 EDT Anavex announces long-lasting effects of ANAVEX 3-71 - Anavex Life Sciences announced long-lasting effect of clinical drug candidate ANAVEX 3-71 in preventing cognitive decline in a transgenic rat model of Alzheimer's disease at the Alzheimer's Association International Conference, AAIC, taking place in San Diego, CA and virtually on July 31 - August 4, 2022. ANAVEX 3-71 or control was administered orally once daily in pre-plaque McGill-R-Thy1-APP transgenic rats and wild-type rats divided into four groups, for seven months. Subsequently, after one month of drug interruption, behavioral tests were performed: Novel Object Recognition, Morris Water Maze, and Social Preference. Biomarker analysis revealed that ANAVEX 3-71 prevents McGill-APP transgenic rats from increasing cortical and hippocampal extracellular Abeta deposition. ANAVEX 3-71 also significantly reduces microglia and astrocytes recruitment towards Abeta-burdened neurons in the hippocampus. In the Novel Object Recognition behavioral test, Tg control rats explored the novel object significantly less than wt control rats. The impairment in Tg rats was completely reversed with ANAVEX 3-71. In the Morris Water Maze behavioral test, the rats showed significant differences in learning. In the Social Preference behavioral test, Tg control rats showed less interaction time with a "stranger rat" than wt control rats. This deficit in Tg rats was entirely reversed with ANAVEX 3-71. This new data strengthens the importance and applicability of Anavex's Precision Medicine SIGMAR1 platform and is consistent with previously reported therapeutic significant and dose-dependent preclinical prevention of Abeta induced biomarker-correlated cognitive impairments with ANAVEX 2-73. Both clinical drug candidates ANAVEX 2-73 and ANAVEX 3-71 activate the sigma-1 receptor. Data suggests that activation of SIGMAR1 results in the restoration of homeostatic function within the body and is pivotal to restoring neural cell balance and the promotion of neuroplasticity.2 Recent independent findings strengthen the understanding of the beneficial effects of SIGMAR1 activation as a compensatory mechanism to chronic CNS diseases. "These results strengthen our SIGMAR1 product platform and validate Anavex's approach to CNS target selection and drug discovery," said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "This data increases Anavex' confidence in the potential of our Precision Medicine technology to address serious neurodegenerative diseases."

07:25 EDT Flora Growth announces cannabis JV with indigenous tribe in Columbia - Flora Growth announced a joint venture agreement with Pharma Indigena Misak Manasr Sas , "the largest indigenous tribe in Colombia, on the development of cultivation best practices, manufacturing, export, and marketing of cannabis and cannabis containing products," said Flora. Under the agreement, Flora will provide Manasr regulatory advice, technical and business support related to product development and distribution, promotion of products to be marketed under the Flora brand portfolio, and cannabis derivatives when needed to complete product production. Additionally, Manasr will work closely with Flora in developing cannabis pharmaceuticals & products and help advance the approvals and authorizations required for exports of cannabis from Colombia.

07:25 EDT Main Street raises dividend 2.3% to 66c - Main Street Capital announced that its Board of Directors declared regular monthly cash dividends of 22c per share for each of October, November and December 2022. These monthly dividends, which will be payable pursuant to the table below, total 66c per share for the Q4 and represent a 2.3% increase from the regular monthly dividends declared for the Q3 and a 4.8% increase from the regular monthly dividends paid for the Q4 of FY21.

07:23 EDT Colliers International acquires controlling interest in PEAKURBAN - Colliers announced it has acquired a controlling interest in PEAKURBAN, one of the fastest growing engineering companies in Australia. The PEAKURBAN senior leadership team will remain significant shareholders of the business under Colliers' unique partnership model. The business will rebrand as "Colliers Engineering & Design" and integrate into Colliers' existing Australian operations. Terms of the transaction were not disclosed. "The expansion of Colliers Engineering & Design into Australia will complement our existing Project Management and Strategic Advisory capability and enhance our service offerings to unlock opportunities and accelerate growth for our clients and people," said John Kenny, CEO Colliers Asia Pacific. "PEAKURBAN's values and culture align strongly with ours and we are delighted to welcome these talented professionals to our organisation."

07:22 EDT Converge Technology's REDNET secures EUR 156M framework contract - Converge Technology Solutions announced in conjunction with its subsidiary REDNET that REDNET secured a large public sector contract in Germany. This contract allows public authorities, local authorities and universities in Rhineland-Palatinate and Saarland to procure computer hardware through REDNET which won no fewer than eight lots and will equip public authorities, local authorities and universities in both German federal states with thin clients, notebooks, servers, laser printers, inkjet printers, Windows tablets, iOS tablets and scanners until May 2025. The institutions in Rhineland-Palatinate equipped by REDNET include the Landtag (state parliament), ministries, municipalities, police and judiciary, as well as universities and state companies organized under private law, the majority of which are publicly owned. In Saarland, among others, ministries, the Landtag, state companies and universities can procure their IT via REDNET in compliance with procurement law.

07:21 EDT mCloud Technologies enters technology continuation agreement with Agnity Global - mCloud Technologies announced that it has entered into a technology continuation agreement with Agnity Global, enabling mCloud to build on the success of its existing relationship with Agnity. The Technology Continuation Agreement will replace the royalty agreement between mCloud and Agnity originally announced on June 21, 2018. Under the terms of the Technology Continuation Agreement, Agnity will pay mCloud a one-time payment of approximately $6M. The new structure allows the parties to continue delivering and supporting Agnity's technology and builds on mCloud's existing license and continued use of Agnity technology across all of the company's AssetCare offerings going forward.

07:21 EDT Evaxion Biotech announces Wegner to resign as CEO, Norlen to succeed - Evaxion Biotech announced the following executive management changes. Lars Staal Wegner has decided to resign as the Company's Chief Executive Officer, CEO. Dr. Wegner will remain with the Company in an advisory role to the Company's new CEO and Board of Directors. In Dr. Wegner's place, the Company has appointed Per Norlen, M.D., PhD. Most recently, Dr. Norlen was Chief Executive Officer of Targinta AB and Chief Medical Officer of Xintela AB.

07:19 EDT Transcode Therapeutics, MD Anderson announce strategic alliance - TransCode Therapeutics announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and diagnostic candidates. Through the alliance, TransCode and MD Anderson scientists will collaborate on preclinical studies to further validate TransCode's therapeutic and diagnostic candidates and to expand the reach of TransCode's discovery engine. The results of these studies will inform future clinical trials with these agents, including trials to be led at MD Anderson. The collaboration has the potential to inform multiple clinical programs in TransCode's pipeline, starting with its lead therapeutic candidate, TTX-MC138, designed to treat multiple metastatic cancers. Future clinical trials will be designed and led by Vivek Subbiah, M.D., Associate Professor of Investigational Cancer Therapeutics at MD Anderson. Prior to a Phase I clinical trial, TTX-MC138 is scheduled to enter a first-in-human Phase 0 clinical trial designed to demonstrate delivery of the therapeutic candidate to metastatic lesions in patients with advanced solid tumors. "We are acutely aware of the expectations that come with a therapeutic approach that has the potential to induce durable regressions of metastatic disease. We are committed to taking every opportunity to fulfill the promise of RNA in cancer," said Michael Dudley, Co-Founder and CEO of TransCode.

07:17 EDT Eliem Therapeutics to discontinue further development of ETX-810 - Eliem Therapeutics reported results from its Phase 2a clinical trial investigating ETX-810 for the treatment of lumbosacral radicular pain. ETX-810 is a novel, new chemical entity prodrug of the bioactive lipid palmitoylethanolamide (PEA) that was evaluated in two Phase 2a clinical trials, one in subjects with diabetic peripheral neuropathic pain and one in subjects with LSRP, commonly referred to as sciatica. In the Phase 2a clinical trial in LSRP, ETX-810 did not achieve statistically significant separation from placebo on the trial's primary endpoint, which assessed the change from baseline to week 4 in the weekly average of the daily pain score measured with the Pain Intensity Numerical Rating Scale. This result is consistent with the lack of separation from placebo observed in the Phase 2a clinical trial in DPNP, as reported in April 2022. Therefore, the Company has elected to discontinue further development of ETX-810. The Company recently provided an update that its capital is sufficient to fund key pipeline catalysts and operations until mid-2024. With the discontinuation of ETX-810, the Company anticipates that its cash runway will extend beyond that time and expects to provide more detail on the extended cash runway in connection with its second quarter 2022 financial results release. The multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluated the efficacy and safety of ETX-810 in 148 subjects with LSRP over four weeks of dosing. Patients were randomized 1:1 to 1,000 mg of ETX-810 twice daily or placebo. ETX-810 was well tolerated in the study, with a safety profile consistent with previous studies. However, the primary endpoint of the study was not achieved, and separation from placebo on the PI-NRS was not observed during the four weeks of dosing.

07:16 EDT Marriott added 17,000 rooms globally during Q2 - The company added roughly 17,000 rooms globally during the second quarter, including approximately 9,200 rooms in international markets and nearly 4,400 conversion rooms.

07:15 EDT Leidos to acquire Cobham Aviation Services Australia's Special Mission business - Leidos announced it has entered into a definitive agreement with Cobham to acquire Cobham Aviation Services Australia's Special Mission business. The Special Mission business provides airborne border surveillance and search and rescue services to the Australian Federal Government. The acquisition is subject to customary closing conditions, including regulatory approvals.

07:10 EDT JetBlue sees Q3 CASM ex-fuel to increase 15%-17% - "I'm very pleased with the team's execution this quarter to position us to return to sustained profitability in the back half of the year. Despite the operational headwinds in April, the subsequent operational investments we made, and the sharp rise in fuel prices throughout the quarter, we exited Q2 with an adjusted pre-tax profit for the month of June, and we look forward to carrying this momentum into Q3 and beyond," said Ursula Hurley, JetBlue's Chief Financial Officer. "For the third quarter, we are forecasting CASM ex-Fuel to increase 15 to 17 percent. We're also tightening our forecast for full-year 2022 CASM ex-Fuel to increase in the range of 11 to 14 percent versus 2019. We expect the heightened level of operational investments to normalize once we get beyond the summer peak. As a result, we expect to see some productivity improvement into the fourth quarter and 2023. We're embarking on a new plan to keep our costs low, focused on cross-functional costs and applying best practices with respect to operational and planning efficiencies. Through the strong underlying momentum in the business and the continued execution of our various strategic initiatives - from the Northeast Alliance to the evolution of our Loyalty program to scaling JetBlue Travel Products, and now our new structural cost program as well - we are setting a foundation to structurally improve our long-term earnings potential."

07:07 EDT Uber sees Q3 gross bookings $29B-$30B - Sees Q3 adjusted EBITDA $440M-$470M. "We became a free cash flow generator in Q2, as we continued to scale our asset-light platform, and we will continue to build on that momentum," said Nelson Chai, CFO. "This marks a new phase for Uber, self-funding future growth with disciplined capital allocation, while maximizing long-term returns for shareholders."

07:04 EDT LGI Homes sees 2022 home closings 7,500 - 8,300 - Active selling communities at the end of 2022 between 100 and 110; Average sales price per home closed between $345,000 and $360,000; Gross margin as a percentage of home sales revenue between 27.0% and 29.0%; Adjusted gross margin as a percentage of home sales revenue between 28.5% and 30.5% with capitalized interest accounting for substantially all the difference between gross margin and adjusted gross margin as a percentage of home sales revenue; SG&A as a percentage of home sales revenue between 10.0% and 11.0%; Effective tax rate between 23.5% and 24.5%

07:03 EDT Marriott reports Q2 comparable systemwide constant dollar RevPAR down 2.9% - Second quarter 2022 comparable systemwide constant dollar RevPAR declined 2.9% worldwide and 14.1% in international markets, while RevPAR increased 1.3% in the U.S. & Canada, compared to the 2019 second quarter.

06:58 EDT Virgin Galactic secures land for astronaut campus in State New Mexico - Virgin Galactic Holdings announced it has secured land to move forward with a new astronaut campus and training facility in the State of New Mexico, near the Company's commercial operations headquarters. The land, located in Sierra County, will be home to a new for exclusive use by Virgin Galactic Future Astronauts and up to three of their guests in advance of a spaceflight from Spaceport America. The master plan for the campus will include training facilities, purposeful accommodations, and tailored experiences as well as an observatory, wellness center, recreation activities, and unique dining options -- all underpinned by Virgin's signature hospitality. Conceptual design of the campus has already begun, and Virgin Galactic plans to complete the build out in parallel with the expansion and capacity of its fleet in New Mexico. The Company is committed to continuing its strong track record of engaging local suppliers.

06:56 EDT SunCoke Energy increases cash dividend 33% to 8c per share - SunCoke Energy announced that its board approved an increased cash dividend of 8c per share of the company's common stock, representing a 33% increase over the regular quarterly cash dividend of 6c per share. The announced dividend is payable on September 1 to stockholders of record at the close of business on August 18.

06:37 EDT Henry Schein announces company-wide restructuring plan - Henry Schein is announcing a company-wide restructuring plan that is "focused on funding the priorities of the strategic plan and streamlining operations and other initiatives to increase efficiency." The company said it expects to record restructuring charges in 2022 and 2023, however an estimate of the amount of these charges has not yet been determined. "Any restructuring charges are expected primarily to include severance pay and facility-related costs. The expense savings realized from this plan are expected to mainly affect 2023 and beyond," the company added.

06:30 EDT Coty signs global travel retail joint business partnership with Ant Group - Coty has officially signed the global travel retail joint business partnership with Ant Group to enhance the cooperation in digitalization. The agreement means that Coty will be the first beauty company to reach the strategic partnership in travel retail to support digital platforms like Alipay and other digital payment methods at a global level through Alipay+, a suite of global cross-border mobile payments and marketing solutions operated by Ant Group. Based on the partnership, Coty will continue expanding the travel retail business through the digital operation powered by Alipay+, by creating brand campaigns via Alipay and other payment platforms, and offering more customized consumer experience. This strategic partnership will extend from China to a wider area of APAC, and furtherly to Coty's global travel retail market. With the signing of this agreement, Coty will go forward hand in hand with Ant Group to boost the development of digital service as well as the travel retail business, and will continue to develop more in-depth cooperation in an all-round way, across precision marketing, omni channel activations, and digital payment solution.

06:26 EDT Integral Ad Science appoints Thomas Joseph as CTO - Integral Ad Science (IAS) announced that it has named Thomas Joseph as CTO, effective August 8. As CTO, Joseph will lead the engineering team to develop and scale new offerings while continuing to evolve existing products. Joseph will report directly to Lisa Utzschneider, CEO of IAS, and will execute on the long-term product vision as part of the senior leadership team. Before joining IAS, he served as SVP Engineering at SiriusXM (SIRI) and Pandora, where he was responsible for the full engineering stack and architecture.

06:22 EDT Allarity to refocus its oncology pipeline strategy away from monotherapies - Allarity Therapeutics announced that its Board of Directors has mandated a refocus of the Company's oncology pipeline strategy away from development of monotherapies towards development of more promising and clinically relevant combination therapies. Following a lengthy and in-depth analysis of current pipeline opportunities, clinical/commercial/ regulatory risks, development costs and timelines, expected availability of funding, and in consultation with Allarity's senior management, its Scientific Advisory Board, or SAB, and external experts, Allarity's Board of Directors has concluded that refocusing the Company's pipeline to development of combination therapies will accomplish the following: Align with the ongoing shift in cancer therapy standard-of-care away from monotherapies toward combination therapies, which are increasingly driving market opportunities and which have shown dramatic increases in patient benefit; Strengthen the Company's ability to attract additional funding from institutional life science investors, which is necessary to support the Company's clinical development activities and future success; Significantly broaden the Company's possibilities for future commercial partnering with larger pharmaceutical companies to maximize the value of its pipeline assets and DRP platform technology; Improve the likelihood of clinical and commercial success of the Company's pipeline assets. The Board's decision also takes into account feedback that the Company recently received from the FDA from a Type C advisory meeting held in Q2 2022, regarding a potential Phase 3 clinical development path for dovitinib as a monotherapy third-line treatment for metastatic renal cell carcinoma. The Company has determined that advancing dovitinib as a monotherapy in adults is no longer commercially viable or in the best interests of its shareholders. However, the drug will continue to be externally developed, via the partnership with OncoHeroes Biosciences, as a potential monotherapy for pediatric cancers. As part of its new strategic pipeline focus, the Company has announced it expects to initiate enrollment in a Phase 1b/2 study of its PARP inhibitor, stenoparib, in combination with its pan-TKI, dovitinib, for the second-line or later treatment of metastatic ovarian cancer by or before Q4.

06:16 EDT Apollo Investment promotes Tanner Powell to CEO - The company has announced the following senior management promotions and Board changes which are effective immediately. Howard T. Widra, who served as Chief Executive Officer since May 2018 and as President from June 2016 to May 2018, has been named Executive Chairman of the Board. Widra will continue to serve as Apollo's Head of Direct Origination. Tanner Powell, who served as President of the Company since May 2018 and Chief Investment Officer for Apollo Investment Management, L.P., the Company's investment adviser since June 2016, has been promoted to Chief Executive Officer of the Company. Ted McNulty, who is a Managing Director in Apollo's Direct Origination business, has been promoted to President of the Company and Chief Investment Officer for AIM. Kristin Hester, who has served as the General Counsel of the Company since May 2020, has been promoted to Chief Legal Officer and Secretary of the Company. Joseph Glatt, who served as the Company's Chief Legal Officer and Secretary since 2011, was promoted to a new role as Partner in Apollo's U.S. Financial Institutions Group. John Hannan, who has served as Chairman of the Board since 2006, will now serve as Vice Chairman of the Board.

06:09 EDT Apollo Investment raises base distribution to 32c per share - Payable on October 11 to shareholders of record as of September 20.

06:07 EDT BP announces further $3.5B share buyback

05:59 EDT KBR reports Q2 adjusted EPS 76c, consensus 65c - Reports Q2 revenue $1.62B, consensus $1.62B. "Building on strong momentum in attractive end markets, we continue to make excellent progress toward KBR's 2025 long-term targets," said Stuart Bradie, president and CEO of KBR. "Themes that favor our capabilities and technologies - national security, defense modernization, global energy security and climate change - continue to be at the forefront of priorities. Combined with the unwavering commitment of our team of teams to deliver on our clients' missions, I am pleased to report that the company posted another outstanding quarter of superb safety results, earnings growth, cash generation and strategic program awards."

05:55 EDT Charles Schwab repurchases $1B of shares from Toronto-Dominion - Charles Schwab (SCHW) announced that it has purchased approximately 15M shares of its nonvoting common stock directly from TD Bank (TD) for $1B. The shares are being acquired pursuant to Schwab's recent repurchase authorization. Under the terms of a repurchase agreement entered into with a subsidiary of TD Bank, the purchase price paid by Schwab is equal to the lowest price per share that TD Bank received in a contemporaneous share sale facilitated with a third-party market maker, which resulted in a purchase price lower than today's closing price.

05:44 EDT Halozyme announces Roche IMscin001 study met its co-primary endpoints - Halozyme (HALO) announced that Roche's (RHHBY) Phase III IMscin001 study evaluating a subcutaneous, or SC, formulation of Tecentriq with Halozyme's Enhanze technology met its co-primary endpoints.

05:36 EDT Nyxoah enters distribution partnership with Acurable SL - Nyxoah announced that the company has entered into a distribution agreement with Acurable SL, a venture-backed medical device company developing wearable technologies for home use, to provide the AcuPebble SA100 home sleep test to OSA patients in Germany. The AcuPebble SA100 is a next-generation wearable home sleep test that uses acoustic signals to diagnose OSA. The patient attaches the reusable AcuPebble sensor to the base of the neck to record sounds generated by the respiratory and cardiac functions. These recorded signals are uploaded to a secure cloud platform through a smartphone application where patented algorithms extract OSA parameters providing an automated diagnostic report within minutes. AcuPebble has demonstrated high levels of sensitivity and specificity for both the apnea-hypopnea index, or AHI, and the oxygen-desaturation index, or ODI, compared with the gold-standard polygraphy test, and is clinically validated through a randomized study published in the BMJ Open. The system is CE marked and has FDA clearance.

05:23 EDT Logitech G, Tencent announce handheld cloud gaming partnership - Logitech G (LOGI) and Tencent Games (TCEHY) announced a partnership to bring a cloud gaming handheld to market later this year that will combine Logitech G's expertise in hardware with Tencent Games' expertise in software services. The new device will support multiple cloud gaming services, and both companies are working with the Xbox Cloud Gaming and NVIDIA GeForce NOW teams, so gamers can play AAA games when they are away from their console or PC.

05:18 EDT ResMed acquires mementor, terms undisclosed - ResMed announced the acquisition of Leipzig-based company mementor; the deal was completed Monday, August 1. With this acquisition, ResMed strengthens its overall sleep portfolio in Germany with a digital solution for insomnia. Founded in 2014 and based in Leipzig, Germany, mementor developed and owns the digital insomnia therapy solution somnio, which is Germany's first and only permanently approved Digital Health Application, or DiGA, in the field of sleep medicine and thus eligible for reimbursement in Germany. It's also compliant with the European Union's data protection requirements under the General Data Protection Regulation, or GDPR. The financial terms of the transaction were not disclosed.

05:12 EDT Yatsen regains compliance with NYSE - Yatsen announced that it has received a letter from the New York Stock Exchange, notifying the company that it has regained compliance with the NYSE's continued listing criterion of a minimum share price as set forth in Section 802.01C of the NYSE Listed Company Manual.